Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Total Revenue of $212.69 million for fiscal year 2025.
TREACE MEDICAL CONCEPTS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $212.69M +1.6% |
$209.36M +11.9% |
$187.12M +31.9% |
$141.84M +50.2% |
$94.42M +64.6% |
$57.37M +45.5% |
| Net Income | -$59.00M -5.8% |
-$55.74M -12.6% |
-$49.53M -15.7% |
-$42.81M -108.3% |
-$20.55M -460.3% |
-$3.67M +14.0% |
| Diluted EPS | -$0.93 -3.3% |
-$0.90 -11.1% |
-$0.81 -5.2% |
-$0.77 -79.1% |
-$0.43 -258.3% |
-$0.12 |
| Total Assets | $190.58M -12.2% |
$217.09M -13.8% |
$251.91M +58.4% |
$159.02M +12.9% |
$140.82M +236.8% |
$41.81M |
| Cash and Equivalents | $10.71M -5.7% |
$11.35M -12.6% |
$12.98M -33.3% |
$19.47M -81.6% |
$105.83M +485.4% |
$18.08M +48.9% |
| Long-Term Debt | $55.58M +4.3% |
$53.31M +0.6% |
$53.01M +0.6% |
$52.71M +79.5% |
$29.36M +0.6% |
$29.19M |
| Stockholders Equity | $87.33M -22.6% |
$112.89M -18.2% |
$137.94M +127.9% |
$60.53M -35.0% |
$93.07M +11893.9% |
$776.0K -75.5% |
| R&D Expense | $20.28M -1.5% |
$20.59M +33.3% |
$15.44M +13.7% |
$13.58M +33.1% |
$10.20M +74.5% |
$5.85M +15.3% |
| Operating Income | -$54.15M +2.8% |
-$55.69M -8.3% |
-$51.43M -47.6% |
-$34.84M -111.0% |
-$16.51M -2031.0% |
$855.0K +124.2% |
| Gross Profit | $169.75M +0.9% |
$168.26M +10.7% |
$151.94M +30.6% |
$116.31M +50.0% |
$77.53M +72.7% |
$44.90M +41.2% |
| Shares Outstanding | — | — | 61.75M +11.0% |
55.63M +2.7% |
54.18M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $50.21M | +11.4% | +6.0% |
| Net Income | September 30, 2025 | -$16.29M | -6.0% | +6.4% |
| Diluted EPS | September 30, 2025 | -$0.26 | -4.0% | +7.1% |
| Total Assets | September 30, 2025 | $196.59M | -7.7% | -4.8% |
| Cash and Equivalents | September 30, 2025 | $7.69M | -36.5% | -4.5% |
| Long-Term Debt | September 30, 2025 | $53.53M | +0.6% | +0.1% |
| Stockholders Equity | September 30, 2025 | $89.19M | -15.0% | -8.6% |
| R&D Expense | September 30, 2025 | $4.68M | -5.7% | -14.9% |
| Operating Income | September 30, 2025 | -$15.68M | -3.6% | +7.6% |
| Gross Profit | September 30, 2025 | $39.71M | +9.9% | +5.2% |
| Shares Outstanding | September 30, 2024 | 62.28M | +1.1% | +0.2% |
- TREACE MEDICAL CONCEPTS, INC. reported Total Revenue of $212.69 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +1.6% in Total Revenue compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Net Income of -$59.00 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -5.8% in Net Income compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Diluted EPS of $0.93 per share (loss) for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -3.3% in Diluted EPS compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Total Assets of $190.58 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -12.2% in Total Assets compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Cash and Equivalents of $10.71 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -5.7% in Cash and Equivalents compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Long-Term Debt of $55.58 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +4.3% in Long-Term Debt compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Stockholders Equity of $87.33 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -22.6% in Stockholders Equity compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported R&D Expense of $20.28 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed a decrease of -1.5% in R&D Expense compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Operating Income of -$54.15 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +2.8% in Operating Income compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Gross Profit of $169.75 million for fiscal year 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +0.9% in Gross Profit compared to the prior fiscal year.
- TREACE MEDICAL CONCEPTS, INC. reported Shares Outstanding of 61.75 million shares for fiscal year 2023.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +11.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: